Y-mAbs cuts 35% of staff; Genentech re-ups Nimble deal; Landos shifts focus; and more
A month after the FDA rejected its neuroblastoma drug, the biotech Y-mabs said it will cut 35% of its workforce to save cash and focus on commercializing its lone approved product, Danyelza.
The FDA rejected its drug omburtamab on Dec. 2, based on questions about the company’s clinical trial and after an advisory committee voted 16-0 against recommending the drug. The cuts will reduce operating expenses by 28%, and give Y-mabs enough cash to get through the first quarter of 2026.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
